Pacira BioSciences reports developments across a commercial portfolio of non-opioid pain management and regenerative health products. Its recurring updates center on EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical pain, ZILRETTA® extended-release intra-articular corticosteroid injection for osteoarthritis, and the iovera° cold-therapy device for targeted nerve pain control.
Company news also covers earnings and product revenue trends, real-world evidence on opioid use and healthcare costs, pipeline development involving ZILRETTA, iovera° and PCRX-201, share repurchases, equity inducement awards, and stockholder governance matters tied to board composition and proxy materials.
Pacira BioSciences, Inc. (NASDAQ:PCRX) will report its fourth quarter and full year 2020 financial results on February 25, 2021, before U.S. market opening. A live conference call and webcast will follow at 8:30 a.m. ET, with participation accessible via a dedicated phone line and on their website. Pacira is committed to non-opioid pain management, focusing on its long-acting local analgesic, EXPAREL®, launched in 2012, and the iovera°® cryoanalgesia device acquired in 2019.
Pacira BioSciences reported preliminary unaudited net product sales of EXPAREL and iovera° totaling $34.9 million and $1.1 million, respectively, for January 2021. Average daily sales for EXPAREL reached 108% of the prior year, signaling ongoing growth despite COVID-19 challenges. The company emphasizes the successful adoption of EXPAREL in elective surgeries and its relevance in expedited recovery protocols. However, COVID-19 continues to negatively impact elective surgical schedules, affecting overall sales.
Pacira BioSciences (Nasdaq: PCRX) announced an equity investment in GeneQuine Biotherapeutics to support gene therapy development for osteoarthritis. The initial investment is €2 million, with an additional €4 million contingent on achieving specific milestones related to its lead product, GQ-303. Up to €2.5 million will be in convertible notes. This investment aligns with Pacira's mission to advance non-opioid pain management solutions. GeneQuine’s gene therapy vectors aim to enhance joint function and reduce pain and inflammation.
Pacira BioSciences (Nasdaq: PCRX) reported preliminary unaudited net revenue of $429.6 million for 2020, a 2.0% increase from 2019. The fourth-quarter net product sales for EXPAREL reached $125.3 million, up from $116.9 million in 2019. Daily sales of EXPAREL were at 109% of the previous year's average for Q4 and 111% for December. Despite COVID-19 disruptions, EXPAREL's growth in elective and non-elective procedures highlights its role in non-opioid pain management. The complete financial results will be reported in Q1 2021.
PACIRA BIOSCIENCES, INC. (NASDAQ: PCRX) will present at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021, at 7:30 AM ET. Investors can access the live audio via the company's website. A replay will be available for two weeks post-event. Pacira is a leader in non-opioid pain management and regenerative health solutions, known for its long-acting local analgesic, EXPAREL®. The company acquired the handheld cryoanalgesia device, iovera⁰, in April 2019 to further its mission of reducing opioid reliance.
Pacira BioSciences (Nasdaq: PCRX) announced preliminary net product sales of $38.1 million for EXPAREL and $0.8 million for iovera° in November 2020, marking a continuation of year-over-year growth despite COVID-19 challenges. The company is optimistic about EXPAREL's increasing adoption in outpatient settings and diverse surgical procedures. However, 2020 sales were affected by pandemic-related elective surgery postponements. The firm will provide ongoing updates on sales for greater transparency as market dynamics evolve post-pandemic.
Pacira BioSciences (NASDAQ: PCRX) will present at the 2020 Piper Sandler 32nd Annual Virtual Healthcare Conference on December 1, 2020, at 11:30 AM ET. The live audio can be accessed via the company’s Events page. A replay will be available for two weeks post-event.
Pacira is known for its non-opioid pain management solutions, including EXPAREL®, a long-acting local analgesic launched in April 2012, and the iovera⁰ system acquired in 2019 for targeted nerve treatment.
Pacira BioSciences (NASDAQ: PCRX) announced that the European Commission has granted marketing authorization for EXPAREL for managing post-operative pain in adults. This approval is based on four Phase 3 studies that showed EXPAREL significantly reduces pain and opioid consumption after surgery. The marketing authorization covers all EU member states, the UK, Iceland, Norway, and Liechtenstein, with a launch planned for late 2021. Since its U.S. launch in 2012, EXPAREL has been administered to over 7.5 million patients.
Pacira BioSciences (Nasdaq: PCRX) reported preliminary unaudited net product sales of EXPAREL at $40.7 million and iovera° at $1 million for October 2020. EXPAREL sales grew by 112% year-over-year, marking five consecutive months of growth. Despite challenges from the COVID-19 pandemic affecting elective surgeries, EXPAREL is increasingly used in various surgical procedures. The company plans to continue monthly sales reports to improve transparency regarding COVID-19's impact.
Pacira BioSciences (NASDAQ: PCRX) will present at the 2020 Jefferies Virtual London Healthcare Conference on November 17, 2020, at 2:05 PM GMT (9:05 AM ET). The presentation will be accessible via the company’s events page, with a replay available for two weeks afterward. Pacira is recognized for its commitment to non-opioid pain management solutions, notably through its long-acting local analgesic EXPAREL®, launched in 2012. The company focuses on reducing opioid reliance in healthcare.